1. This article discusses the design of potent, selective and drug-like RGD αvβ1 small molecule inhibitors derived from non-RGD α4β1 antagonists.
2. The article outlines the process of designing these inhibitors and provides evidence for their efficacy.
3. It also discusses the potential applications of these inhibitors in medical research and drug development.
The article is written by a reputable author, Richard Hatley, who has extensive experience in the field of medical research and drug development. The article is published in a peer-reviewed journal, ChemMedChem, which adds to its credibility. The article provides evidence for its claims through references to other studies and experiments conducted by the author himself. Furthermore, it does not appear to be biased or one-sided as it presents both sides of the argument equally. However, there are some points that could be explored further such as potential risks associated with using these inhibitors or possible counterarguments that could be presented in order to provide a more comprehensive overview of the topic. Additionally, there is no mention of promotional content or partiality which suggests that the article is reliable and trustworthy overall.